Table 2.
Cases with EGFR Exon 19 C-Helix Deletion
| ID | Amino Acid Change | Gender | Age, Year | Histology | Smoking Status | TKI | Best Response | PFS (Months) |
|---|---|---|---|---|---|---|---|---|
| 1 | S752_I759del | Female | 48 | Adenocarcinoma | Never smoker | Gefitinib + erlotinib | PR | 12.0 |
| 2 | S752_I759del | Female | 64 | Adenocarcinoma | Never smoker | - | - | - |
| 3 | S752_I759del | Female | 67 | Adenocarcinoma | Never smoker | - | - | - |
| 4 | S752_I759del | Male | 52 | Adenocarcinoma | Prev/curr smoker | - | - | - |
| 5 | S752_I759del | Female | 67 | Adenocarcinoma | Never smoker | Icotinib | PR | 18.0 |
| 6 | S752_I759del | Male | 70 | Adenocarcinoma | Prev/curr smoker | Icotinib | SD | 6.5+ |
| 7 | S752_I759del | Female | 52 | Adenocarcinoma | Never smoker | Gefitinib | PR | 17.0+ |
| 8 | S752_I759del | Female | 44 | Adenosquamous carcinoma | Never smoker | Icotinib | PD | 2.0 |
| 9 | S752_I759del | Male | 71 | Adenocarcinoma | Prev/curr smoker | Icotinib | PR | 54.0+ |
| 10 | S752_I759del | Female | 47 | Adenocarcinoma | Never smoker | Icotinib | PR | 8.0 |
| 11 | S752_I759del | Female | 67 | Sarcomatoid carcinoma | Never smoker | |||
| 12 | S752_I759del | Male | 53 | Adenocarcinoma | Never smoker | Gefitinib | SD | 12.0 |
| 13 | S752_I759del | Female | 69 | Adenocarcinoma | Never smoker | Icotinib | PR | 34.5 |
| 14 | S752_I759del | Male | 62 | Adenocarcinoma | Prev/curr smoker | |||
| 15 | S752_I759del | Female | 59 | Adenosquamous carcinoma | Never smoker | Gefitinib | SD | 4.5+ |
| 16 | S752_I759del | Female | 49 | Adenocarcinoma | Never smoker | Erlotinib | PR | 6.5 |
| 17 | S752_I759del | Female | 47 | Sarcomatoid carcinoma | Never smoker | |||
| 18 | S752_I759del | Male | 63 | Adenocarcinoma | Prev/curr smoker | Gefitinib | PR | 9.5 |
| 19 | S752_I759del | Female | 66 | Adenocarcinoma | Never smoker | Icotinib | PD | 2.0 |
| 20 | A750_E758del | Male | 65 | Adenocarcinoma | Prev/curr smoker | - | - | - |
| 21 | A750_E758del | Male | 51 | Adenocarcinoma | Never smoker | - | - | - |
| 22 | A750_E758del | Female | 64 | Adenocarcinoma | Never smoker | Gefitinib | PR | 7.0 |
| 23 | A750_E758delinsP | Female | 62 | Adenocarcinoma | Never smoker | Gefitinib | PR | 9.0 |
| 24 | L747_A755delinsSKG | Female | 50 | Adenosquamous carcinoma | Never smoker | - | - | - |
| 25 | E749_K754del | Male | 75 | Adenocarcinoma | Never smoker | - | - | - |
| 26 | T751_A755delinsNY | Female | 64 | Adenocarcinoma | Never smoker | Icotinib | PR | 7.0 |
| 27 | T751_E758del | Female | 49 | Adenocarcinoma | Never smoker | - | - | - |
| 28 | T751_I759delinsG | Female | 36 | Adenocarcinoma | Never smoker | Gefitinib | PR | 18.0 |
| 29 | T751_I759delinsLD | Female | 40 | Adenocarcinoma | Never smoker | Icotinib | PR | 15.5 |
| 30 | T751_I759delinsN | Female | 65 | Adenocarcinoma | Never smoker | Icotinib | PR | 22.0 |
| 31 | T751_I759del | Female | 58 | Adenocarcinoma | Never smoker | - | - | - |
| 32 | T751_L760delinsNL | Male | 53 | Adenosquamous carcinoma | Never smoker | Icotinib | SD | 5.0 |
| 33 | T751_D761delinsLY | Female | 39 | Adenocarcinoma | Never smoker | Icotinib | PR | 9.5+ |
| 34 | P753_I759delinsG | Male | 60 | Adenocarcinoma | Prev/curr smoker | - | - | - |
| 35 | A750_E758delinsP | Female | 46 | Adenocarcinoma | Never smoker | - | - | - |
| 36 | A750_I759delinsG | Male | 56 | Adenocarcinoma | Prev/curr smoker | |||
| 37 | A750_E758del | Male | 65 | Adenocarcinoma | Prev/curr smoker | Gefitinib | PR | 8.0+ |
| 38 | A750_E758del | Male | 51 | Adenocarcinoma | Never smoker | - | - | - |